Pulmatrix, Inc. (PULM) stock
PULMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.37+0.04 (+3.01%)
Close on Nov 17, 2026Market cap $5.00MP/E –Yield –
Earnings
Pulmatrix's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Oct 15, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q3 FY2025
$0
-100.0% on a year earlier
EPS, Q3 FY2025
-$0.24
-$0.71 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Pulmatrix's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Oct 15, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 15, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 16, 2025before the open | $0 | -100.0% | -$0.24 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025before the open | $0 | -100.0% | -$0.42 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 21, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 8, 2024before the open | $400.00K | -77.8% | -$0.71 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024before the open | $1.60M | -11.1% | -$1.59 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 10, 2024before the open | $5.90M | +293.3% | $0.23 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 28, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | $1.80M | -5.3% | -$1.03 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023before the open | $1.80M | +38.5% | -$1.04 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 12, 2023before the open | $1.50M | +25.0% | -$1.22 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | $1.90M | +72.7% | -$1.45 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022before the open | $1.30M | – | -$1.36 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022before the open | $1.20M | – | -$1.51 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 29, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021after the close | $1.10M | – | -$0.15 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 11, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 23, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 12, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 7, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 14, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Pulmatrix has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Pulmatrix puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Pulmatrix filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Update
- Results
- Update
- Results
- Results
- Results
- Update
- Update
- Update
- Results
See a number that looks wrong?